

Recombinant Plague (*Yersinia pestis*) Vaccine

Catalog No. NR-15893

This reagent is the property of the U.S. Government.

Lot No. 7371

Manufacturing Date: AUG2007

For research use only. Not for human use.

Contributor:

National Institute of Allergy and Infectious Diseases, National Institutes of Health

Manufacturer:

Avecia Biologics Ltd., Manchester, United Kingdom

Product Description:

NR-15893 is a sterile suspension of RypVax™, recombinant plague vaccine, containing recombinant F1 (rF1) and V (rV) antigens from *Yersinia pestis* produced in *Escherichia coli*. The purified antigens (160 µg/mL rF1 and 160 µg/mL rV) were adjuvanted with Alhydrogel. Antibodies to rF1 have been shown to be protective against bubonic plague while antibodies to rV have been shown to enhance protection against inhalation plague.¹ This vaccine combined both antigens and was expected to protect against both forms of the disease.

Note: NR-15893 is provided through BEI Resources for research use only. It is not for human use.

Material Provided:

Each vial contains approximately 0.8 mL of purified recombinant antigen proteins (160 µg/mL rF1 and 160 µg/mL rV) adjuvanted with 0.26% w/w Alhydrogel.

Packaging/Storage:

NR-15893 was packaged aseptically in single-use glass vials. The product is provided at 2°C to 8°C on refrigerated bricks and should be stored at 2°C to 8°C immediately upon arrival. Do not freeze NR-15893.

Citation:

Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Recombinant Plague (*Yersinia pestis*) Vaccine, NR-15893."

Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 5th ed.

Washington, DC: U.S. Government Printing Office, 2009; see www.cdc.gov/od/ohs/biosfty/bmbl5/bmbl5toc.htm.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

References:

- Williamson, E. D. and C. F. Oyston. "Acellular Vaccines against Plague." *Yersinia: System Biology and Control*. Eds. E. Carniel and B. J. Hinnebusch. Norfolk, United Kingdom: Caister Academic Press, 2012. 123-142.

ATCC® is a trademark of the American Type Culture Collection.

